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Cutaneous metabolism and pharmacology have been 
the focus of increased scientific inquiry in the past 2 
decades. However, in the past few years, attention has 
been focused specifically on the effects of topically ap-
plied drugs in infants as different qualitatively or quan-
titatively from their effects in adults. 
Prior to 1972, it was known that brain damage oc-
curred in animals with prolonged blood levels of 1 Itg/ml 
h e xachlorophene, and that washing newborn babies 
with a standard 3% hexachlorophene liquid soap for 3- 5 
days resulted in significant blood levels of the compound. 
However, this knowledge was not disseminated widely 
enough to prevent the tragic deaths of infants after the . 
use of baby powder contaminated with 6.6% hexachlo-
rophene [1]. This incident highlighted the need for in-
creased understanding of drug effects not only from the 
viewpoint of the skin as a target organ, but also of 
percutaneous penetration and resultant blood levels; the 
affinity of other body tissues for drugs and their metabo-
lites; metabolites which may result from the effect of the 
skin itself acting on the drug; and the infant's much 
greater ratio of surface area to body weight, allowing 
the infant to percutaneously absorb proportionately 
greater quantities of topical medication than an adult. 
Although tissue distribution of most drugs has not been 
studied in infants, it is known that such distribution 
often depends on age. For example, in infants and chil-
dren with a given plasma level, of drugs such as barbi-
turates, morphine and tetracycline, the brain tissue level 
may exceed that of the adult. Thus, drugs and chemicals 
that penetrate infant skin may produce effects different 
than those penetrating adult skin. 
NEONATAL PHARMACOLOGY AND DEVELOPMENT 
OF ORGAN SYSTEMS 
Cutaneous permeability of pre term infants is greater than in 
adult skin. Once absorbed, a given drug may be more toxic for 
a neonate than for an adult. Factors such as drug absorption, 
protein binding, metabolism, distribution and excretion may be 
altered because several organ systems such as the hepatic, renal 
and central nervouS systems are not structurally and function-
ally fully developed. Morselli [2] includes the following physi-
qlogic distinctions that exist between the neonate and the adult: 
(a) Lower blood pressure and val'iable blood flow patterns; (b) 
Brain and liver make up a greater proportion of body weight; 
(c) Changes in drug excretion due to incomplete development 
of kidney giving different pH proportions of urine and blood; 
(d) Body compartments are of different (relative and absolute) 
proportions; (e) Total body water is larger and the ratio of 
extra/intra-cellular water is considerably elevated; (0 Adipose 
tissue is less. 
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The neonate shows decreased plasma protein binding which 
leads to drug toxicity at lower doses. Also, albumin is qualita -
tively different and has less binding potential which increases 
the likelihood of drug displacement and toxicity at lower doses. 
Drug metabolism is altered because of immature metabolic 
pathways in the liver. Drugs requiring metabolism for detoxi-
fication and deactivation may show longer half-lives in neo-
nates. Usually, the deficient metabolic pathways in the neonate 
are the oxidative and reductive syst ems while hydrolytic reac-
tions may show relatively little difference between the newborn 
and the adult with some drugs. Depending on the drug, conju-
g~tive and other synthetic pathways may show small or large 
dIfferences between neonates and adults in the metabolism of 
drugs [3]. 
Drugs requiring renal excretion may show a similar prolon-
gation of half-life in the neonate because of immature renal 
function. At birth, glomerular filtration rate in full-term infants 
is half that of an adult and only reaches adult levels at 1 yr of 
age. Tub~lar function is even more greatly reduced, and less 
than maXllTIal ability to concentrate urine in pre term infants 
often leads to metabolic acidosis. 
An infant must undergo considerable neurological develop-
ment. In proportion to total body weight, the infant's brain 
weight represents a larger share than in the adult. Myelinization 
starts in the second trimester and is completed slowly dW'ing 
infancy. At least 2 factors may be important in increasing 
infantile brain susceptibility to drug-induced seizures: The 
blood-brain barrier is more permeable in newborns than in 
adults and preterm infants are more susceptible to seizure 
activity because of low carbonic anhydrase levels. 
Body SUI/ace Area 
Several physiologic processes such as cardiac output, blood 
volume, glomerular filtration and organ development closely 
correlate with body surface area. As a human grows in volume 
so does the surface area but at a much slower rate. Adults hav~ 
relatively small surface area while infants have relatively large 
surface areas. This serves to maximize the dose of a topical 
drug in the newborn. The infant sW'face area is greater than 
would be expected from weight alone. Proportions of newborn 
to adult with respect to weight, surface area and length are 
respectively 1:21, 1:9 and 1:3.3 [4]. 
Drugs are often dosed according to body swface area in 
pediatrics and in all ages with various chemotherapy protocols. 
T his principle of dosing is not clinically used to any great extent 
in t~e dosing of topical medications for infants. Perhaps dosing 
based on body surface is appropriate for some medications but 
all rules for dosing fail for preterm and neonatal infants. The 
established dosing rules based on body sill'face area become 
useful in older infants. Studies with salicylic acid show that a 
proportionately larger systemic dose is delivered in infants than 
in adults with topical applications of the same product. It is 
postulated that this is due to differences in body surface area, 
i.e., body weight ratios, but differences in cutaneous and other 
organ system kinetics probably playa role. 
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Growth Rate 
The postnatal growth of preteI'm infants resembles the 
growth rate of fetuses of the same size rather than that of full-
term infants of the same postnatal age. 
PHARMACOLOGY OF INFANT SKIN 
Since the ability of the skin to accept, transfer and metabolize 
drugs is clearly related to its structural and biochemical devel-
opment, a rapid review of these processes appears to be in 
order. 
Epidermis 
The human embryo of 2-4 weeks is covered by the single 
layered periderm which resembles amniotic epithelium and 
permits exchange of nutrients and other substances between 
the fetus and amniotic fluid. The stratum germinativum, de-
veloping in the 4-week embryo, gives rise to the epidermis and 
its appendages. At 3 mo of fetal life, the epidermis is 2-4 cell 
layers thick and by the 5th month, keratohyalin granu les appear 
within epidermal cells. By the 6th mo, functioning melanocytes 
are present within the basal layer. At birth , the stratum cor-
neum is fully developed in mammalian species, including man, 
and its ultrastructure is virtually indistinguishable from that of 
an adult. 
Percutaneous penetration is affected by multiple factors in-
cluding the physical properties of the penetrant and the vehicle, 
skin hydration and temperature, and epidermal and dermal 
metabolism. The main barrier to penetration is the stratum 
corneum. Adult human studies indicate that regional body 
variations in skin penetration result from differences in the 
thickness of the stratum corneum and to a slighter degree, 
differences in amount of epidermal appendages. 
Infant epidermis is less thick than adult epidermis [5] and it 
is assumed that the stratum corneum is proportionately also 
thinner. However, we know little about the barrier function 
differences as they relate to stratum corneum thickness in 
infants and less about the barrier qualities of the newborn 
keratin as opposed to that of the adult. Pediatricians have long 
used the newborn's skin appearance as a criterion for assessing 
prematurity or postmaturity, as well as disease states such as 
the Gray syndrome or diabetes mellitus. 
Most evidence regarding differences in percutaneous absorp-
tion between newborn and adu lt skin comes from studies in 
preterm infants. Skin permeability in pre term infants was eval-
uated with topically applied phenylephrine [6]. Infants 28 to 34 
weeks of gestational age had a rapid blanching response lasting 
from 30 min to 8 hr. Infants 35 to 37 weeks in most instances 
failed to exhibit blanching. This suggested that preterm infants 
have immature epidermal barrier function. 
While there is increased water content in normal full -term 
infant epidermis, some factors predispose to transepidermal 
water loss (TWL) in immature infants. These include thinner 
stratum corneum, increased water content and increased 
permeability. However, healthy term newborns have lower 
TWL's than adults. This could be due to a more efficient barrier 
in term n.e>yborns or due to the influence of eccrine gland 
activity on TWL in adults [7]. Again, skin microphotographs 
show that a newborn infant has a much thicker stratum cor-
neum than an 1-mo"0Id infant and that this covering is shed 
within the first few days of life [5]. 
Biosynthesis and percutaneous absorption of a wide variety 
of lipids takes place in infant skin. Abdominal skin from young 
adults can synthesize a number of different lipids in proportions 
similar to that occurring in infant foreskin, but older adult 
abdominal skin is less active. Differences in lipid synthesis may 
also exist at various body sites as well as in different age groups 
[8]. 
Cyclic nucleotide metabolic studies are variable, but there 
may be some differences between adult and newborn or preterm 
infant skin. Subtle differences were detected between the cyclic 
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AMP-dependent protein kinases of neonatal human skin and 
adult human skin but no prominent distinguishing features 
were noticeable [9]. N ewborn mouse epidermis contains aden-
ylate cyclase responsive to f3-adrenergic stimulation, but is 
relatively insensitive to isoproterenol stimulation. Cyclic AMP 
levels are rapidly elevated following injection of isoproterenol 
or epineptuine and the elevations can be blocked by propran-
olol. Mitotic rate in epidermis is essentially the same in infants 
as in young adults. 
Appendages 
The trans-appendageal route probably accounts for a rela-
tively small amount of drug absorption both in adults and 
infants. There has been neither a qualitative or quantitative 
difference demonstrated in drug absorption in different age 
groups. 
Hair development starts in humans during the third fetal 
month and most follicles are formed before birth. The earliest 
hair (lanugo) is fine, soft, unmedullated, poorly pigmented and 
distributed widely. In the newborn, the hair growth phases are 
synchronized with about 80% of hairs in the telogen phase. A 
temporary alopecia may occur during dyssynchronization of 
growth. 
Eccrine glands are anatomically completely formed by the 
5th fetal month. Apocrine glands are well developed at the 7th-
8th fetal month , producing a milky-white fluid containing water 
lipids, protein, reducing sugars, ferric iron and ammonia. Se~ 
baceous glands start differentiating at about 13-15 weeks of 
fetal life and almost begin to produce sebum. Their growth and 
activity up to and immediately after birth is governed, in part, 
by maternal androgen and endogenous steroid production. The 
shedding of sebaceous gland cells into amniotic fluid late in 
gestation forms the basis of the nile blue sulfate stain test of 
fetal maturity [10]. The sebaceous cells stain orange or brown 
while epidermal fetal squames stain blue. Cytological count of 
10% fat-laden cells occur at 36 weeks while a 20% count occurs 
at 40 weeks of pregnancy. 
Dermis 
A birth, the dermis is about 2-4 mm thick. There is little 
evidence to suggest age differences in the uptake of dJ"ugs into 
the dermis, but the release of dl"ugs out of the dermis may differ 
because of the differences in water binding qualities and the 
differences in ground substances in the dermis. The dermis of 
the human embryo starts as an undifferentiated cellular myxo-
matous tissue in which fibrils first appeal" between 2 a nd 4 mo 
of age. Collagen and elastic fibers al"e found between 20 to 40 
weeks of life. Elastic tissue continues to increase postnatally 
and to contain less lysine than does fetal tissue . The ground 
substance is mainly composed of the mucopolysaccharides, 
hyaluronic acid, chondroitin sulfate B (dermatan sulfate) and 
water. Neonatal skin is often edematous because of dermal 
loosely bound watel" and sodium excess, most of which is lost 
within a few days. 
Subcutaneous Fat Tissue 
Subcutaneous fat first appears in the 14th week of fetal life 
and accumulates mainly in the last trimester of pregnancy. The 
preterm infant has a poorly developed fat supply, a relatively 
large surface area and a small body mass. All of these factors 
are disadvantages in trying to maintain body temperature. 
Brown adipose tissue, which is practically absent in the adult, 
is found in speciflc anatomical areas of the newborn infant, e.g., 
in the interscapular region, at the base of the neck and in the 
posterior abdominal wall. This tissue performs a central role in 
postnatal regulation of body temperatme. A newborn infant 
regulates body temperature not by shivering but by increased 
oxidation of fatty acids within the adipose t issue. Therefore, the 
effect of cold is depletion of brown adipose tissue with slight 
influence on white adipose tissue. It is unknown how adipose 
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tissue change affects topically applied drugs and percutaneous 
absorption in infants, but several lipid soluble drugs such as 
DDT and lindane, are stored in white adipose tissue in adults. 
DERMA TOTO XI CO LOGY AND INFANT SKIN 
Several commonly used drugs and chemicals have been re-
ported as the cause of percutaneous toxicity in infants. In many 
of these reported cases, the preterm infant appears to be at 
greatest risk because of incomplete epidermal barrier to pene-
tration of toxic drugs and chemicals. There are many reports of 
less commonly encountered drugs and percutaneous toxicity in 
infants which are not included in this review. 
Phenol, Resorcinol and Castellani's Paint 
Phenol and phenolic derivatives have been frequently re-
ported as causes of percutaneous toxicity. An outbreak of 
percutaneous poisoning with epidemiological follow-up oc-
curred in 1967 with a laundry product containing pentachloro-
phenol. Twenty newborn infants developed symptoms of pro-
fuse, generalized diaphoresis, fever, tachycardia, tachypnea, 
hepatomegaly and acidosis. Nine infants became severely ill 
and 2 babies died. High concentrations of the chemical were 
found in nursery linens which provided a source for percuta-
neous absorption evidenced by toxic serum and tissue levels 
[11]. Several infant deaths due to topical application of resor-
cinol have been reported. Methemoglobinemia, cyanosis, he-
molytic anemia, drowsiness, shallow respiration and hemoglo-
binuria are also problems which have followed topical resorcinol 
application in infants [12]. 
Boric Acid 
Historically boric acid proved to be a significant toxic hazard 
to infants because it was commonly applied in .talcum powders, 
ointments or solutions in 5-10% concentrations to inflamed and 
occluded areas of diaper dermatitis. Several infant fatalities 
have been reported from percutaneous boric acid toxicity and 
it should no longer be used on infant skin [13]. 
Salicylic Acid 
In 1946, Weiss and Lever reviewed percutaneous salicylate 
intoxication and found reports of 13 fatal cases, 10 of which 
were children under 3 yr of age [14]. Symptoms were those of 
salicylism. 
Epinephrine 
Epinephrine (1:1000,0.1 mI) was applied locally to a hemor-
rhaging circumcision area instead of the usual 1:100,000. The 
child was 2 days old. The patient soon showed tachycardia of 
220/min, local pallor of the penis and base of the shaft as well 
as perioral acrocyanosis. The case illustrated the local and 
systemic complications of absorbed epinephrine specially in the 
newborn infant [15]. 
Corticosteroids 
Systemic effects from percutaneous absorption of topically 
applied corticosteroids in infants are frequently reported in the 
literature and appear to exhibit greater toxicity if the steroid is 
fluorinated with significant glucocorticoid potency and the in-
fant is preterm, low birth-weight, and has severe inflammation 
or extensive denuded areas of skin. 
Infants with active atopic dermatitis were treated for 15 days 
with uniform quantities of topical 0.1% betamethasone valerate 
ointment in one group and 1% hydrocortisone ointment in a 
subsequent group [16]. Polyethylene occlusion was used in both 
groups. Adrenocortical function was decreased on the second 
posttreatment day in 75% of infants using fluorinated steroid 
versus no evidence of suppression in the hydrocortisone group. 
Thus, with topical fluorinated steroids, chronic suppression of 
adrenal axis function and impairment of growth is probably a 
significant risk factor evidenced in infants. Unlike the infant 
groups, adult groups were also studied and axis function re-
covered rapidly when treatment was stopped. 
Greater than one-third of the applied dose is systemically 
absorbed in infants with active atopic dermatitis. Topical hy-
drocortisone-induced suppression of the hypothalamic-pitui-
tary-adrenal-axis in infants is minimal and rapidly reversible. A 
more prolonged suppression may be seen with topical fluori-
nated steroids and side effects similar to those seen with sys-
temic administration of corticosteroids are possible [17]. 
Estrogens 
In infants of both sexes, pseudoprecocious puberty has re-
sulted from application of topical estrogen ointments for 2-18 
mo periods with 2-10 daily applications [18]. There has been 
intense pigmentation of mammillary areolae, the linea alba and 
genitals with mammary enlargement and growth of pubic hair. 
Female infants have developed vaginal discharge and bleeding. 
Hexachlorophene 
Chlorinated hydrocarbons are neurotoxic chemicals (cyto-
toxic to nerve cells) producing characteristic signs of CNS 
toxicity if given acutely in a sufficient high dose. Factors con-
tributing to hexachlorophene toxicity in infants include a 
greater number of exposures to the drug, increased concentra-
tion of the drug, absence of adequate rinsing, presence of large 
areas of abraded skin, hepatic, biliary or renal disease and low 
birth weight. UV -lights (bili-lites) help to dechlorinate (detox-
ify) the hexachlorophene and exert a protective effect. General 
suggestions for use of hexachlorophene include: limit exposure 
to 1-2 baths, do not use in infants under 1200 gm or under 35 
weeks of age or where large areas of abraded skin or hepatic 
biliary or renal disease are present and follow with immediat~ 
and thorough rinsing [19]. Histopathology of the CNS in infants 
with hexachlorophene intoxication has shown vacuolar enceph-
alopathy with brain stem reticular formation [20]. 
Lindane 
Lindane is another chlorinated hydrocarbon and neurotoxic 
agent. A 4-mo-old premature infant had a single application of 
lindane over the entire body for 24 hr with subsequent washing. 
New·ological testing 2 days later showed marked mental motor 
retardation. Serum level of lindane 20 hI' after the bath showed 
a level of 0.1 mg/mI (normal <0.001 Ilg/ ml). This level is 10-
fold higher than that previously reported in children and was 
seen with the then standard recommendation of only one ap-
plication for 24 ill· [21]. CNS toxicity due to prolonged appli-
cation of lindane has also been seen in older children. The 
increased serum levels in infants corresponds to the increased 
blood and brain levels seen in newborn versus adult guinea pigs 
after topical application of 1% lindane lotion [22]. 
Chlorhexidine 
Low serum levels of the antimicrobial skin cleanser, chlor-
hexidine, without apparent clinical effect, were detected in 
newborn infants with intact skin who were bathed in a standard 
manner [23]. Pre-term babies had more readily detectable 
serum levels than full-term infants. 
DISCUSSION 
:rhere is much to be learned about percutaneous penetration 
and the resultant dermatopharmacology and dermatotoxicol-
ogy of infant skin. Although full-term infant skin may provide 
a functioning barrier to absorption similar to adults, it appears 
that the preterm infant is at much greater risk of suffering 
toxicity from topically applied drugs and chemicals. Further-
more, little is known about differences in dermal clearance of 
drug absorbed through the epidermis of full-term infants and 
adults, differences which ultimately could represent a variable 
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determining cutaneous toxicity as important as the stratum 
corneum barrier. 
Cutaneous metabolic and detoxification pathways have not 
been determined for most drugs. It is known, however, that 
some topically applied drugs are metabolized in the skin pro-
ducing metabolites different from those the same drug would 
produce by a different route of administration. Although several 
systems are not fully established in newborns, it remains un-
known whether variations exist in cutaneous metabolism and 
detoxification between pre term infants, full-term infants and 
adults. 
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